Inalways - Asset Resilience Ratio
Inalways (5398) has an Asset Resilience Ratio of 10.16% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Inalways working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Inalways's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Inalways (5398) total assets.
Liquid Assets Composition Over Time
This chart breaks down Inalways's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Inalways strategic investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$58.64 Million | 10.16% |
| Total Liquid Assets | NT$58.64 Million | 10.16% |
Asset Resilience Insights
- Moderate Liquidity: Inalways has 10.16% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Inalways Industry Peers by Asset Resilience Ratio
Compare Inalways's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521 |
Drug Manufacturers - Specialty & Generic | 0.35% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS
IS:ECILC |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Teyi Pharmaceutical Group Co Ltd
SHE:002728 |
Drug Manufacturers - Specialty & Generic | 9.66% |
Annual Asset Resilience Ratio for Inalways (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Inalways.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.33% | NT$56.03 Million ≈ $1.77 Million |
NT$600.79 Million ≈ $18.93 Million |
+0.04pp |
| 2024-12-31 | 9.29% | NT$60.65 Million ≈ $1.91 Million |
NT$653.17 Million ≈ $20.58 Million |
+5.17pp |
| 2023-12-31 | 4.12% | NT$22.92 Million ≈ $722.17K |
NT$556.64 Million ≈ $17.54 Million |
+0.37pp |
| 2022-12-31 | 3.75% | NT$22.84 Million ≈ $719.62K |
NT$608.73 Million ≈ $19.18 Million |
-4.68pp |
| 2021-12-31 | 8.43% | NT$54.60 Million ≈ $1.72 Million |
NT$647.84 Million ≈ $20.41 Million |
+1.98pp |
| 2020-12-31 | 6.44% | NT$41.71 Million ≈ $1.31 Million |
NT$647.31 Million ≈ $20.39 Million |
-2.37pp |
| 2019-12-31 | 8.82% | NT$58.96 Million ≈ $1.86 Million |
NT$668.56 Million ≈ $21.06 Million |
-3.87pp |
| 2018-12-31 | 12.69% | NT$79.91 Million ≈ $2.52 Million |
NT$629.72 Million ≈ $19.84 Million |
+7.12pp |
| 2017-12-31 | 5.57% | NT$43.31 Million ≈ $1.36 Million |
NT$777.58 Million ≈ $24.50 Million |
+1.74pp |
| 2016-12-31 | 3.83% | NT$29.43 Million ≈ $927.33K |
NT$769.13 Million ≈ $24.23 Million |
+3.11pp |
| 2015-12-31 | 0.71% | NT$2.45 Million ≈ $77.16K |
NT$343.08 Million ≈ $10.81 Million |
-- |
About Inalways
Mediera Corporation manufactures electronic and power supply components in Taiwan. It is also involved in the medical biotechnology business. The company offers medicines, health food, and medical device, etc. Mediera Corporation was founded in 1967 and is based in New Taipei City, Taiwan.